FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 5, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Neuromyelitis OpticaNeuromyelitis Optica Spectrum DisorderNMO Spectrum Disorder

Interventions

DRUG

Efgartigimod Alfa Injection

Efgartigimod+IVMP; IVMP; Efgartigimod

DRUG

High-dose intravenous methylprednisolone

Efgartigimod+IVMP; IVMP; Efgartigimod

All Listed Sponsors

lead

Tianjin Medical University General Hospital

OTHER

NCT06497374 - FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack | Biotech Hunter | Biotech Hunter